Sec Form 4 Filing - Konus Advisory Group, Inc. @ AntriaBio, Inc. - 2014-03-26

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Konus Advisory Group, Inc. 2. Issuer Name and Ticker or Trading Symbol AntriaBio, Inc. [ ANTB] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) 890 SANTA CRUZ AVENUE 3. Date of Earliest Transaction (MM/DD/YY) 03/26/2014 (Street) MENLO PARK, CA94025 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 03/31/2014 A 1,057,693 ( 2 ) A $ 275,000 5,057,693 ( 1 ) D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Warrant to purchase common stock $ 1.25 03/31/2014 J( 3 ) 234,700 03/31/2014 03/31/2019 Common Stock 234,700 ( 3 ) 234,700 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Konus Advisory Group, Inc. 890 SANTA CRUZ AVENUE MENLO PARK, CA94025 X Signatures /s/ Hoyoung Huh 04/09/2014 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Konus Advisory Group, Inc. owns 5,057, 693 shares of common stock of the Issuer. Mr. Elam and Dr. Hoyoung Huh are significant stockholders, managing members and members of the board of directors of Konus Advisory Group, Inc. Mr. Elam and Dr. Huh share voting and dispositive power of the shares of the Issuer's common stock held by Konus Advisory Group, Inc. ( 2 )On March 26, 2014, AntriaBio, Inc. (the "Company" or "AntriaBio, Inc.") entered into a repayment agreement (the "Repayment Agreement") with Konus Advisory Group, Inc. ("Konus"). Pursuant to the terms of the Repayment Agreement, AntriaBio, Inc. agreed to repay to Konus $1,182,644, representing the total amounts due and owing to Konus for services rendered by Konus and its consultants to the Company (the "Balance") as set forth in the Konus Agreements (as defined in the Repayment Agreement) through, (i) the issuance of $275,000 worth of shares of our common stock (the "Payment Shares") with such Payment Shares to be valued at $0.26 per share and (ii) a cash payment or series of cash payments totaling $907,644 to be paid at such time as mutually agreed to by Konus and the Company. ( 3 )As set forth on the Company's Current Report on Form 8-K filed with the SEC on November 15, 2013, on November 14, 2013, the Company issued a 14% promissory note in the principal amount of $250,000 (the "Konus Note") to Konus in order to evidence funds Konus loaned to the Company. Pursuant to the terms of the Konus Note, the principal balance of the Note is due at the earlier of, (i) November 1, 2014 or (ii) ten days after the closing of an equity financing that raises at least three million dollars. As set forth in Item 1.01 of the Company's Current Report on Form 8-K filed with the SEC on April 1, 2014, on March 31, 2014, the Company completed an initial close of an equity financing for aggregate proceeds of approximately $5 million. As a result, the Company agreed to pay the outstanding principal and interest on the Konus Note within ten (10) days after the closing of the PIPE Financing and we agreed to issue to Konus a warrant (the "Konus Warrant") to purchase 234,700 shares of

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.